- Tariffs and uncertainty, coupled with slow stimulus activity in China, are delaying biopharma investments.
- Slowdown in pharmaceutical spending in China is impacting companies like Novartis, with potential effects from US generic market entries.
Alexion Reports 7% Revenue Growth Driven by U.S. Oncology Market
What happened
Alexion reported total revenue of $13.5 billion, reflecting 7% growth at constant exchange rates, while core EPS grew 14% to $2.08. Oncology revenue reached $21.9 billion for the first nine months, with Enhertu revenue growing 35% overall, including nearly 50% growth in the U.S. market.
From fool.com
Why it matters
The U.S. market growth occurred amid generic competition, while China is implementing volume-based procurement, which is impacting new drug regimens. This dynamic occurs as pharmaceutical spending slows in China, potentially affecting companies like Novartis, and delaying biopharma investments due to tariffs and uncertainty.
The slowdown in pharmaceutical spending in China is impacting companies like Novartis, with potential effects from US generic market entries.
From fool.com